General MedicationsORALStandard
XALKORI
CRIZOTINIB
Standard Dose
20MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview XALKORI is listed in Drugs@FDA under application 217581 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CRIZOTINIB Form and strength CAPSULE, PELLETS;ORAL - 20MG Sponsor PF PRISM CV Submission history Latest submission status date: 2023-09-07 00:00:00.
Structured Monograph
Clinical summary
Approval overview XALKORI is listed in Drugs@FDA under application 217581 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CRIZOTINIB Form and strength CAPSULE, PELLETS;ORAL - 20MG Sponsor PF PRISM CV Submission history Latest submission status date: 2023-09-07 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.